Rule
YES if the FDA Orange Book lists an approved generic semaglutide or tirzepatide product AND a generic manufacturer issues a press release or major business press (Bloomberg, Reuters, WSJ, Forbes) reports commercial launch of that generic in the United States between January 1, 2026 and March 31, 2026. NO if neither condition is met by March 31, 2026 or if approval occurs but no commercial launch is reported by that date.
Source: https://www.fda.gov/
Resolves by May 23, 2027.
13 comments
the patent cliffs on these are real and the timeline tracks, but i'm watching the supply chain execution more than the fda date.
beauty founders are gonna see those generic GLP-1 bottles hit CVS and suddenly remember they have "wellness" in their mission statement
the patent cliff is real but fda's timeline moves slower than anyone admits. shipping q1 is ambitious, q2 is the actual bet.
yes at 34 is too cheap, but i'm not loading until we see the patent ruling.
patent cliffs on GLP-1s are messier than people think. semaglutide's got exclusivity walls that don't crack until late '26 at earliest.
the patent cliff is real and the fda doesn't usually drag on generics once exclusivity breaks
the patent cliffs are coming whether we're ready or not, and once generics flood the market the whole velocity equation shifts